Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global generic injectables market was valued at USD 61.34 Billion in 2025, driven by rising healthcare needs and the introduction of supportive regulatory policies across the globe. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2026-2035, with the values likely to rise USD 130.00 Billion by 2035 by 2035.
Base Year
Historical Period
Forecast Period
The market is witnessing a surge in drug approvals of generic injectables by health regulatory agencies. For instance, in April 2024, Gland Pharma Limited received FDA approval for its generic Eribulin Mesylate Injection to treat breast cancer.
Recent market trends reveal consolidation via mergers and acquisitions among the key companies to boost market share and expand product portfolios.
The oncology segment covers a significant market share due to the rising burden of cancer, which increases the demand for chemotherapy treatments that often require generic injectables.
Compound Annual Growth Rate
7.8%
Value in USD Billion
2026-2035
*this image is indicative*
Generic injectables are similar to their brand-name counterparts in terms of active ingredients, clinical performance, and intended use, among others. They are administered generally through intramuscular or intravenous routes. Generic injectables offer a faster therapeutic effect, higher bioavailability, and can be formulated for slow and sustained release. The rising patent expiration of branded drugs is boosting the market entry of their generic versions, which are typically lower in price and show similar efficacy and safety profiles. The increasing prevalence of chronic diseases and the growing aging population significantly contribute to the rising market demand for generic injectables. Further, supportive policies and initiatives by the government also fuel the market growth by encouraging the use of generic drugs and ensuring faster approval processes for first-time generics.
Surge in Drug Approvals of Generic Injectables to Affect the Market Landscape Significantly
The market is witnessing a surge in drug approvals of generic injectables by health regulatory agencies such as the United States Food and Drug Corporation (FDA). For instance, in April 2024, an India-based generic injectable manufacturer Gland Pharma Limited received FDA approval for its generic Eribulin Mesylate Injection (0.5 mg/mL single-dose vial) to treat breast cancer. The product, which Gland Pharma co-developed with a research-oriented pharmaceutical product development company Orbicular Pharmaceutical Technologies Private Ltd, is expected to be the first generic intravenous drug for this condition in the United States. The rise in approval of new generic injectables, accelerated by the presence of a supportive regulatory framework, is anticipated to influence the market dynamics.
Launch of New Products to Meet Rising Generic Injectables Market Demand
In March 2024, Meitheal Pharmaceuticals, Inc., a generic injectables company based in Chicago, announced recent business progress to support a sustainable drug supply in the United States following its generic injectables portfolio expansion in September 2023. The company is preparing to launch up to 20 new products in 2024 spread across various therapeutic areas and has invested over USD 100 million in generic research and development over the past six years. Additionally, the generic injectables manufacturer recently launched multiple presentations of bupivacaine hydrochloride injection (an anesthetic used for surgical, therapeutic, diagnostic, and obstetrical procedures). The rising introduction of sustainably manufactured and priced generic injectables is poised to augment market demand.
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
“Generic Injectables Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Market Breakup by Container Type
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Oncology Segment Leads Market Share by Application
Based on the application, the market is segmented into oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others. The oncology segment covers a significant market share due to the rising burden of cancer, which increases the demand for chemotherapy treatments that often require generic injectables. Generic carboplatin and cisplatin are platinum-based, injectable chemotherapeutic drugs that are commonly used in curative regimens and combination therapies. Further, cardiovascular and Infectious segments also hold a high market value owing to its efficacy and rapid onset of action of various generic injectables in treating cardiovascular conditions and infectious diseases.
Market Segmentation Based on Container Type is Anticipated to Witness Substantial Growth
Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others. The market share is driven by the rising need for reliable and cost-effective containers that are compatible with a wide range of drug formulations. Vial is the traditional container type and is commonly used due to its affordability, particularly for high-volume production. Additionally, the ease of manufacture and the simplicity of design make it a preferred choice for many pharmaceutical companies.
Based on the region, the market covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, with each region contributing to the overall dynamics of the market. North America holds the largest market share, valued at USD 33 billion in 2023, which can be attributed to the increasing burden of chronic diseases and the growing aging population. For instance, the American Cancer Society’s annual cancer statistics report estimated that new cancer cases will surpass 2 million in the United States in 2024, which indicates the need for effective and affordable generic drugs including generic injectables.
Europe also holds a high market value, with the market size estimated to be USD 13.5 billion in 2023, owing to the rising healthcare needs and the presence of a favorable regulatory environment. Asia Pacific is projected to witness exponential growth driven by increased government initiatives that promote the uptake and manufacture of generic injectables.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
The global pharmaceutical giant Pfizer has a strong presence in the generic injectables market. Acquired in 2015, its subsidiary Hospira specializes in injectable drugs and infusion technologies.
Headquartered in Israel, Teva is one of the largest generic drug manufacturers in the world. The company offers a range of generic injectable products in multiple therapeutic areas including pain management and oncology.
Baxter International Inc. is a global leader in generic injectables, specializing in anesthesia and critical care domain. The company is popular for its innovative delivery systems and premixed injectable drugs.
In October 2023, Novartis completed the Spin-off of its generics and biosimilars business, Sandoz, which is a key player in the generic injectables market, focusing on therapeutic areas such as oncology, immunology, and endocrinology.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Fresenius SE & Co. KGaA, Endo, Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Viatris Inc. (Mylan N.V.), Biocon, Sanofi, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd, among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Container Type |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share